Isotretinoin
- Generic Name
- Isotretinoin
- Brand Names
- Absorica, Accutane, Amnesteem, Claravis, Clarus, Epuris, Myorisan, Sotret, Zenatane
- Drug Type
- Small Molecule
- Chemical Formula
- C20H28O2
- CAS Number
- 4759-48-2
- Unique Ingredient Identifier
- EH28UP18IF
- Background
Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne. It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in the United States. The first isotretinoin-cont...
- Indication
Isotretinoin is indicated to treat severe recalcitrant nodular acne and patients ≥12 years enrolled in the iPLEDGE program.
- Associated Conditions
- Acne conglobata, Neuroblastoma (NB), Rosacea, Sezary Syndrome, Early Mycosis Fungoides (MF), Refractory Acne vulgaris, Severe Recalcitrant nodular acne
- Associated Therapies
- -
Vitamin E in Preventing the Side Effects of Isotretinoin in Former and Current Smokers Who Are Receiving Isotretinoin to Prevent Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00003599
Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas
- Conditions
- Interventions
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00003564
Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment
- Conditions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT00089258
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer
- Conditions
- First Posted Date
- 2004-07-26
- Last Posted Date
- 2011-05-12
- Lead Sponsor
- Hoag Memorial Hospital Presbyterian
- Registration Number
- NCT00002506
- Locations
- 🇺🇸
Bloomington Hospital, Bloomington, Indiana, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸St. Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States
Biological Therapy Plus Chemotherapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
- Conditions
- First Posted Date
- 2004-07-22
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- University of New Mexico
- Target Recruit Count
- 35
- Registration Number
- NCT00003585
- Locations
- 🇺🇸
University of New Mexico Cancer Research & Treatment Center, Albuquerque, New Mexico, United States
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
- Conditions
- First Posted Date
- 2004-05-24
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Rush University Medical Center
- Registration Number
- NCT00003405
- Locations
- 🇺🇸
Rush-Riverside Cancer Center, Kankakee, Illinois, United States
🇺🇸Cook County Hospital, Chicago, Illinois, United States
🇺🇸Rush Cancer Institute, Chicago, Illinois, United States
Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer
- Conditions
- First Posted Date
- 2004-05-11
- Last Posted Date
- 2012-07-11
- Target Recruit Count
- 320
- Registration Number
- NCT00002737
- Locations
- 🇧🇪
Onze Lieve Vrouw Ziekenhuis Aalst, Aalst, Belgium
🇧🇪Algemeen Ziekenhuis Middelheim, Antwerp, Belgium
🇳🇱Groot Ziekengasthuis 's-Hertogenbosch, Hertogenbosch, Netherlands
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- Drexel University College of Medicine
- Registration Number
- NCT00003619
- Locations
- 🇺🇸
Medical College of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Medical College of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00021359
- Locations
- 🇺🇸
Hunterdon Regional Cancer Center, Flemington, New Jersey, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County, Mount Holly, New Jersey, United States
High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1
- Registration Number
- NCT00078988
- Locations
- 🇺🇸
Children's Hospital and Health Center - San Diego, San Diego, California, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Fairview University Medical Center - University Campus, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.